Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus rituximab versus standard care in severe systemic lupus erythematosus
NL-OMON60085Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in systemic lupus erythematosus (SLE) comparing Belimumab + rituximab with Standard of care (2 arms). Primary endpoint: Treatment failure rate during the 2 years study period. Started Oct 2018; status: completed.
02
Drugs
belimumabrituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON60085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60085.